Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) EPS (Basic) (2019 - 2025)

Historic EPS (Basic) for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to -$0.18.

  • Keros Therapeutics' EPS (Basic) rose 8723.4% to -$0.18 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6, marking a year-over-year increase of 13071.02%. This contributed to the annual value of -$5.0 for FY2024, which is 376.15% up from last year.
  • Per Keros Therapeutics' latest filing, its EPS (Basic) stood at -$0.18 for Q3 2025, which was up 8723.4% from -$0.76 recorded in Q2 2025.
  • Keros Therapeutics' EPS (Basic)'s 5-year high stood at $3.66 during Q1 2025, with a 5-year trough of -$1.41 in Q3 2024.
  • Moreover, its 5-year median value for EPS (Basic) was -$1.1 (2022), whereas its average is -$0.75.
  • In the last 5 years, Keros Therapeutics' EPS (Basic) plummeted by 26984.59% in 2022 and then soared by 40247.93% in 2025.
  • Keros Therapeutics' EPS (Basic) (Quarter) stood at -$0.3 in 2021, then crashed by 269.85% to -$1.1 in 2022, then dropped by 21.82% to -$1.34 in 2023, then rose by 8.25% to -$1.23 in 2024, then surged by 85.36% to -$0.18 in 2025.
  • Its EPS (Basic) stands at -$0.18 for Q3 2025, versus -$0.76 for Q2 2025 and $3.66 for Q1 2025.